首页 > 市场调查报告书 > 製药

生物製剂分子标靶治疗学

市场调查报告书

商品编码

1861046

TIGIT抑制剂市场:临床试验与市场机会预测(2026年)

Global TIGIT Inhibitors Drugs Clinical Trials & Market Opportunity Outlook 2026

出版日期: 2025年11月01日 | 出版商:

KuicK Research | 英文 160 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

TIGIT抑制剂市场：临床试验及市场机会展望（2026）报告结果及亮点

预计首个TIGIT抑制剂将于2030年核准
正在进行临床试验的TIGIT抑制剂：超过40种药物
按公司、适应症和阶段划分的全球TIGIT抑制剂临床研发管线概览
超过40种正在进行临床试验的TIGIT抑制剂概览
全球TIGIT抑制剂市场动态
竞争格局

TIGIT抑制剂的需求及本报告的意义

随着人们对TIGIT在免疫逃脱中的作用及其增强癌症免疫疗法的潜力的认识不断加深，TIGIT抑制剂市场正在迅速发展。本报告分析了不断扩展的TIGIT抑制剂领域，并全面展望了这一极具前景的治疗类别的最新科学进展、临床试验和未来商业前景。儘管许多癌症对现有疗法存在抗药性，但抑制免疫检查点的新方法的需求日益增长，使得TIGIT抑制剂的研发成为当务之急。

本报告追踪该领域的最新进展，并提供关键见解，帮助投资者、研究人员和临床医生在这个高风险、高回报的市场中把握机会。透过检视临床潜力和商业机会，本报告强调了TIGIT抑制剂在更广泛的癌症领域中的策略意义，并突显了其在癌症治疗中日益增长的重要性。

本报告包含的临床研究和临床试验资讯

本报告全面深入分析了TIGIT标靶抑制剂的主要临床试验，提供了不同适应症、试验申办者、地区和研发阶段的宝贵数据。 TIGIT抑制剂推动了临床研发管线的发展，但了解其在特定癌症中的潜力至关重要。TIGIT抑制剂的临床试验正在测试其在多种实体肿瘤中的疗效，包括非小细胞肺癌、胃癌和黑色素瘤。正在进行的试验将TIGIT抑制剂与PD-1/PD-L1抑制剂、化疗和其他免疫疗法合併使用，以增强抗肿瘤免疫反应。

本报告也详细介绍了试验申办方，包括大型製药公司和新兴生技公司，有助于展现推动该领域创新发展的利害关係人。从地理上看，这些临床试验正在北美、欧洲和亚洲进行，体现了全球参与，反映了人们对TIGIT抑制剂治疗潜力的广泛兴趣。因此，本部分对于需要掌握临床开发进展的学术研究人员以及商业决策者来说都是重要的参考资料。

参与TIGIT抑制剂研发的主要公司

本报告详细回顾了积极从事TIGIT抑制剂研发的主要公司，包括罗氏、吉利德科学和默克等製药公司，以及Arcus Biosciences、Compugen和Vir Biotechnology等创新生物技术公司。领先的TIGIT抑制剂研发公司目前拥有丰富的研发管线，针对多种癌症适应症。主要製药公司正在评估单药疗法和与PD-1/PD-L1抑制剂联合的疗法，以增强免疫反应。本报告重点在于这些公司的研究方法和临床进展，为利害关係人清晰展现竞争格局。

展望TIGIT抑制剂领域未来发展方向的报告

本报告展望了TIGIT抑制剂在癌症免疫治疗领域的未来发展前景。儘管临床试验持续产生令人鼓舞的数据，但TIGIT抑制剂很可能发挥越来越重要的作用，尤其是在联合治疗方案中，这些方案可以克服目前常用疗法（例如PD-1/PD-L1抑制剂）的限制。 TIGIT抑制剂能够增强对其他免疫检查点抑制剂抗药性的肿瘤的免疫反应，代表着癌症领域中尚未满足医疗需求的重要治疗途径。此外，目前正在积极研究预测患者对TIGIT抑制剂反应的生物标记物，这有望实现个别化治疗并改善临床疗效。

本报告预测，未来将有更多TIGIT抑制剂上市，重点是与其他免疫疗法、化疗甚至放射疗法合併使用。随着更多临床试验数据的出现，TIGIT抑制剂成为癌症免疫疗法基石的潜力日益凸显，这将为患者带来希望，并为所有投资于此快速发展领域的投资者带来机会。

First TIGIT Inhibitor Drug Approval Expected By 2030
TIGIT Inhibitors Drugs In Clinical Trials: > 40 Drugs
Global TIGIT Inhibitors Drugs Clinical Pipeline Insight By Company, Indication and Phase
Insight On More Than 40 TIGIT Inhibitors Drugs In Clinical Trials
Global TIGIT Inhibitors Drugs Market Dynamics
Competitive Landscape

TIGIT Inhibitors Need & Why This Report?

The market for TIGIT inhibitors is rapidly evolving, with growing recognition of the role of TIGIT in immune evasion and its potential to enhance cancer immunotherapy. This report provides an essential analysis of the expanding TIGIT inhibitor landscape, offering a comprehensive overview of recent scientific advances, clinical trials, and the future commercial prospects of this promising therapeutic class. While many cancers remain resistant to current treatments, a growing need exists for the development of new ways to inhibit immune checkpoints, making the development of TIGIT inhibitors of highest importance.

This report tracks developments currently taking place within the sector, providing key insights for investors, researchers, and clinicians are navigating this high risk, high reward market. By examining both the clinical potential and commercial opportunities, this report highlights the strategic relevance of TIGIT inhibitors in the broader oncology field and underlines their growing importance for the treatment of cancer.

Clinical Studies & Trials Insight Included In Report

The report provides comprehensive insight into main clinical trials of the inhibitors targeting TIGIT, offering valued data on different indications, trial sponsors, geographical regions, and phases of development. While TIGIT inhibitors progress through the clinical pipeline, it becomes paramount to understand their potential in certain cancers. Clinical trials for TIGIT inhibitors are testing the inhibitor's efficacy in different solid tumors such as NSCLC, gastric cancer, melanoma, and many more. Trials are underway to study a combination of TIGIT inhibitors with PD-1/PD-L1 inhibitors, chemotherapy, and other immunotherapies for improving anti-tumor immune responses.

The report also details trial sponsors, including big pharmaceutical players and emerging biotech, which helps paint a picture of the stakeholders involved in driving innovation in this space. From a geographical perspective, these trials are ongoing across North America, Europe, and Asia, with global participation reflecting widespread interest in the therapeutic potential of TIGIT inhibition. This section therefore is an important tool for commercial decision makers as well as academic researchers who need to keep up to date with the momentum within the clinical development landscape.

Leading Companies Engaged In R&D Of TIGIT Inhibitors

The report provides an in-depth review of the major companies actively pursuing research and development activities for TIGIT inhibitors, whether pharmaceutical companies such as Roche, Gilead Sciences, and Merck or innovative biotech firms including Arcus Biosciences, Compugen, and Vir Biotechnology. Leading developers of TIGIT inhibitors are currently working with deep pipelines targeting multiple cancer indications. Large pharma companies are evaluating monotherapies and combinations, often in association with PD-1/PD-L1 inhibitors to enhance immune responses. It highlights the research approaches and clinical development for such companies and provides a clear picture of the competitive landscape to stakeholders.

Report Indicating Future Direction Of TIGIT Inhibitors Segment

This report looks ahead to the future of the TIGIT inhibitors segment in cancer immunotherapy. While clinical trials continue to churn out encouraging data, TIGIT inhibitors will increasingly take center stage, especially in combination regimens that can obviate limitations seen with currently deployed approaches such as PD-1/PD-L1 inhibitors. The ability of TIGIT inhibitors to enhance immune responses in tumors resistant to other immune checkpoint inhibitors makes the drugs a key therapeutic modality in cancers with unmet needs. Furthermore, active research into biomarkers predictive of patient response to TIGIT inhibition may allow for tailored treatments and improvement in clinical outcome.

The report predicts that more TIGIT inhibitors will enter the market, with a strong emphasis on their combination with other immunotherapies, chemotherapy, and even radiation therapy. As more data is unveiled from clinical trials, the potential for TIGIT inhibitors to become a cornerstone in cancer immunotherapy becomes much more real, bringing hope to patients and opportunities to all those invested in this burgeoning segment.

1. Introduction To TIGIT Inhibitors

1.1 Overview
1.2 Mechanistic Insights Into TIGIT Inhibitor Function
1.3 Clinical Strategies For Targeting TIGIT

2. Global TIGIT Inhibitors Clinical Trials Overview

2.1 By Company
2.2 By Country
2.3 By Indication
2.4 By Phase

3. Global TIGIT Inhibitors Clinical Pipeline By Company, Indication and Phase

3.1 Research
3.2 Preclinical
3.3 Phase I
3.4 Phase I/II
3.5 Phase II
3.6 Phase III

4. Global TIGIT Inhibitors Market Outlook

4.1 Current Clinical & Market Trends
4.2 Future Market Opportunities

5. TIGIT Inhibitors Market Trends by Indication

5.1 Cancer
5.2 Autoimmune & Inflammatory Disorders
5.3 Microbial Infections

6. TIGIT Inhibitors Market Trends By Region

6.1 US
6.2 China
6.3 South Korea
6.4 Australia
6.5 Europe

7. Integrating TIGIT Inhibition With Other Therapeutic Modalities

8. Dual Checkpoint Blockade - TIGIT With PD-1/PD-L1

9. Global TIGIT Inhibitors Market Dynamics

9.1 Market Drivers & Opportunities
9.2 Commercialization Challenges & Solutions

10. Competitive Landscape

10.1 Akeso Biopharma
10.2 AstraZeneca
10.3 BeOne Medicines
10.4 Bio-Thera Solutions
10.5 BioNTech
10.6 Compugen
10.7 FutureGen Biopharmaceutical
10.8 Merck & Co / MSD
10.9 Nanjing Sanhome Pharmaceutical
10.10 OriCell Therapeutics
10.11 Phio Pharmaceuticals
10.12 Roche
10.13 Shanghai Henlius Biotech
10.14 Shanghai Junshi Biosciences
10.15 Simcere Pharmaceutical Group

简介目录图表

List of Figures

Figure 1-1: TIGIT/DNAX Accessory Molecule-1 Pathway
Figure 1-2: TIGIT Inhibitors - Proposed Mechanism of Action
Figure 1-3: TIGIT Inhibitor - Mechanism Of Action
Figure 1-4: Monoclonal Antibody - Binding Efficacy
Figure 1-5: Bispecific Antibodies - Binding Efficacy
Figure 1-6: Small Molecule Drugs - Advantages
Figure 2-1: Global - TIGIT Inhibitors Clinical Trials by Company (Number of Drugs), 2026
Figure 2-2: Global - TIGIT Inhibitors Clinical Trials by Country (Number of Drugs), 2026
Figure 2-3: Global - TIGIT Inhibitors Clinical Trials by Indication (Number of Drugs), 2026
Figure 2-4: Global - TIGIT Inhibitors Clinical Trials by Phase (Number of Drugs), 2026
Figure 4-1: Global TIGIT Inhibitors Market - Future Market Opportunities
Figure 5-1: TIGIT - Impact On Tumor Microenvironment
Figure 5-2: TIGIT In Cancer Immune Escape
Figure 5-3: PACIFIC-8 Phase 3 (NCT05211895) Study - Initiation & Completion Year
Figure 5-4: STAR-221 Phase 3 (NCT05568095) Study - Initiation & Completion Year
Figure 5-5: STAR-121 Phase 3 (NCT05502237) Study - Initiation & Completion Year
Figure 5-6: Rilvegostomig - Ongoing Phase 3 Clinical Trials
Figure 5-7: TIGIT Mechanisms In Tregs
Figure 5-8: Microbial Infections - TIGIT Signaling & Immune Suppression
Figure 5-9: Microbial Infections - Therapeutic Targeting Of TIGIT
Figure 7-1: TIGIT Therapy Combinations
Figure 7-2: TIGIT Inhibitor Combination Trials
Figure 9-1: Global TIGIT Inhibitors Market - Drivers & Opportunities
Figure 9-2: Global TIGIT Inhibitors Market - Commercialization Challenges & Solutions

List of Tables

Table 5-1: TIGIT Expression On Immune Cells
Table 5-2: TIGIT Expression & Regulation & Tregs & Other Cells
Table 5-3: TIGIT Ligands & Functional Mechanisms
Table 5-4: TIGIT In Autoimmune Diseases
Table 5-5: TIGIT Function In Immune Cells During Infection

02-2729-4219

+886-2-2729-4219

License/价格

TIGIT抑制剂市场:临床试验与市场机会预测(2026年)

Global TIGIT Inhibitors Drugs Clinical Trials & Market Opportunity Outlook 2026

目录

第1章 TIGIT抑制剂的介绍

第2章 TIGIT抑制剂的全球临床试验概要

第3章 TIGIT抑制剂的全球的临床实验平台(各企业，各适应症，各期)

第4章全球TIGIT抑制剂市场展望

第5章 TIGIT抑制剂的各适应症市场趋势

第6章 TIGIT抑制剂市场趋势(各地区)

第7章 TIGIT阻碍和其他的治疗方法的整合

第8章双重检查点抑制－TIGIT与其他疗法的整合-PD-1/PD-L1的TIGIT

第9章 TIGIT抑制剂的全球市场动态

第10章竞争情形